DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Information source: Duke University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Brain and Central Nervous System Tumors

Intervention: hydroxyurea (Drug); imatinib mesylate (Drug); vatalanib (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Duke University

Official(s) and/or principal investigator(s):
David A. Reardon, MD, Study Chair, Affiliation: Duke Cancer Institute


RATIONALE: Imatinib mesylate, vatalanib, and hydroxyurea may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vatalanib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving imatinib mesylate and vatalanib together with hydroxyurea may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate and vatalanib when given together with hydroxyurea in treating patients with recurrent or relapsed malignant glioma.

Clinical Details

Official title: Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Maximum tolerated dose and dose-limiting toxicity of imatinib mesylate and vatalanib when administered with hydroxyurea

Secondary outcome:




Antiangiogenic effects

Detailed description: OBJECTIVES:

- Determine the maximum tolerated dose and dose-limiting toxicity of imatinib mesylate

and vatalanib when administered with hydroxyurea in patients with recurrent or relapsed grade 3 or 4 malignant glioma.

- Determine the safety and tolerability of this regimen in these patients.

- Determine the single-dose and repeated-dose pharmacokinetic profiles of imatinib

mesylate (in serum) and vatalanib in these patients.

- Determine the pre- and post-treatment antiangiogenic effects of this regimen in these

patients, using dynamic contrast-enhanced MRI to evaluate changes in the extent of vascular permeability, perfusion, and relative tumor blood volume.

- Determine whether changes in diffusion-weighted images MRI (quantitated by apparent

diffusion coefficient maps) correlate with tumor cellularity and tumor cell death in patients treated with this regimen.

- Determine antitumor activity of this regimen, in terms of radiographic response,

progression-free survival, and overall survival, in these patients. OUTLINE: This is an open-label, dose-escalation study of imatinib mesylate and vatalanib. Patients receive oral vatalanib once daily, oral imatinib mesylate once daily, and oral hydroxyurea twice daily on days 1-28*. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: *Patients receive vatalanib alone daily on days 1-7 followed by vatalanib, imatinib mesylate, and hydroxyurea on days 8-35 in course 1 only. Cohorts of 3-6 patients receive escalating doses of imatinib mesylate and vatalanib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD. After completion of study treatment, patients will be evaluated for 28 days. PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.



- Histologically confirmed malignant glioma

- Grade 3 or 4 disease

- In first, second, or third recurrence or relapse

- Multifocal disease allowed


- Karnofsky performance status 70-100%

- Life expectancy ≥ 12 weeks

- Absolute neutrophil count > 1,500/mm^3

- Hemoglobin > 9 g/dL

- Platelet count > 100,000/mm^3

- Potassium normal*

- Total calcium (corrected) normal*

- Magnesium normal*

- Phosphorus normal*

- aspartate transaminase (AST) and alanine transaminase (ALT) < 2. 5 times upper limit

of normal (ULN)

- Bilirubin < 1. 5 times ULN

- Negative proteinuria by dipstick OR total urinary protein ≤ 500 mg with creatinine

clearance ≥ 50 mL/min by 24-hour urine collection

- Creatinine < 1. 5 times ULN OR creatinine clearance > 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No acute or chronic liver or renal disease

- left ventricular ejection fraction (LVEF) ≥ 45% by Multi Gated Acquisition Scan

(MUGA) or echocardiogram

- No complete left bundle branch block

- No obligate use of a cardiac pacemaker

- No congenital long QT syndrome

- No history of or current ventricular or atrial tachyarrhythmias

- No clinically significant resting bradycardia (i. e., heart rate < 50 beats/minute)

- No right bundle branch block with left anterior hemiblock (bifascicular block)

- No uncontrolled hypertension ≥ grade 2, history of labile hypertension, or history of

poor compliance with an antihypertensive regimen

- No concurrent unstable angina pectoris or angina pectoris within the past 3 months

- No congestive heart failure (CHF)

- No history of CHF or arrhythmias requiring concurrent digoxin or verapamil

- No acute myocardial infarction within the past 3 months

- No other impaired cardiac function or clinically significant cardiac disease

- No peripheral neuropathy ≥ grade 2

- No unresolved diarrhea ≥ grade 2

- No uncontrolled diabetes

- No active or uncontrolled infection requiring intravenous antibiotics

- No impaired gastrointestinal (GI) function or GI disease that may significantly alter

the absorption of vatalanib, hydroxyurea, and/or everolimus, including any of the following:

- Ulcerative disease

- Uncontrolled nausea, vomiting, or diarrhea

- Malabsorption syndrome

- Small bowel resection

- No other concurrent severe and/or uncontrolled medical condition that would preclude

study participation or compliance

- No known HIV positivity

- No other primary malignancy that is clinically significant or requires active

intervention NOTE: *Supplement allowed PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- More than 2 weeks since prior tumor biopsy (4 weeks since prior surgical resection)

- Prior polifeprosan 20 with carmustine implant (Gliadel® wafer) allowed at discretion

of principal investigator

- Prior hydroxyurea allowed

- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and 1 week for

metronomic-dosed chemotherapy [e. g., daily etoposide hydrochloride or cyclophosphamide]) and recovered

- More than 4 weeks since prior radiotherapy and recovered

- More than 2 weeks since prior immunotherapy and recovered

- More than 4 weeks since prior investigational drugs and recovered

- No prior platelet-derived growth factor- or vascular endothelial growth

factor-directed therapies

- More than 2 weeks since prior hematopoietic colony-stimulating factor (e. g.,

filgrastim [G-CSF] or sargramostim [Granulocyte-macrophage colony-stimulating factor (GM-CSF)])

- Prior epoetin alfa allowed

- No concurrent warfarin

Locations and Contacts

Duke Comprehensive Cancer Center, Durham, North Carolina 27710, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: July 2005
Last updated: June 3, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017